

GlycanAge and ExoEarth Corp. Form Strategic Collaboration to Advance Biological Age Testing and Aging Research in Japan

Partnership covers the expansion of glycan-based biological age testing across Japan and a joint research programme bridging glycan biomarkers & exosome science

LONDON, UNITED KINGDOM, August 20, 2026 /EINPresswire.com/ --

[GlycanAge](#), the company behind the world's leading glycan-based inflammaging test, and ExoEarth Corporation, a Japanese life sciences company developing the EXOCURE® platform, today announced a strategic collaboration to expand access to biological age testing in Japan and to pursue joint research into the biology of aging. The partnership, formalised through a Memorandum of Understanding (MOU), spans both commercial and scientific objectives.

“

Japan is one of the world's most advanced longevity markets...Combining our glycan biomarkers with ExoEarth's expertise in exosome biology opens up exciting avenues for understanding how we age.”
Nikolina Lauc, CEO, GlycanAge

Together, GlycanAge and ExoEarth share a vision of a future in which people everywhere can understand, measure, and actively shape the way they age. Through this collaboration, the two companies aim to bring glycan-based biological age testing to the heart of Japan's scientific, healthcare, and longevity communities, establishing it as a trusted foundation for a new era of preventive, personalised health.

The partnership also unites two complementary frontiers of aging science: GlycanAge's glycan biomarkers of immune-system health and ExoEarth's pioneering work in

exosome biology. The two companies will work toward designing and implementing a longitudinal joint research program using GlycanAge testing to evaluate changes over time in



GlycanAge |  **ExoEARTH**
Exosomes create a New Standard of Medicine.

Advancing Biological Age Testing and Aging Research in Japan Together

Advancing Biological Age Testing and Aging Research
in Japan Together

biological-age and immune-related indicators associated with the EXOCURE® program. Details regarding participant numbers, measurement intervals, intervention conditions, and the research governance framework will be determined following the necessary scientific, medical, ethical, and regulatory review.

"Japan is one of the world's most advanced longevity markets, and ExoEarth is an ideal partner both to bring GlycanAge to more people here and to explore new science together. Combining our glycan biomarkers with ExoEarth's expertise in exosome biology opens up exciting avenues for understanding how we age." - Nikolina Lauc, CEO, GlycanAge

"From my own experience of continuously tracking my GlycanAge since my sixties, I have come to believe that age is more than just a number - it can serve as an important indicator for understanding and managing our own health. Through this collaboration with GlycanAge, we aim to promote a new culture of healthy longevity built around a simple cycle: measure, understand, act, and measure again. Together, we hope to bring this approach to the world."- Takashi Nishihira, CEO, ExoEarth Corporation

About GlycanAge: GlycanAge is a biotech company built on more than 30 years of glycoscience research and over 350 peer-reviewed scientific publications. Its flagship at-home test measures inflammaging and immune system health, capturing changes that can precede standard bloodwork. Learn more at glycanage.com.

About ExoEarth Corporation: ExoEarth is a Japanese life sciences company developing the EXOCURE® platform, which is based on extracellular vesicles derived from stem cells obtained from human exfoliated deciduous dental pulp and integrates clinical collaboration, biological data, and longevity research. Learn more at exoeearth.co.jp.

Vladi Mihaylova, Chief Marketing Officer
GlycanAge Ltd.
vladi@glycanage.com

This press release can be viewed online at: <https://www.einpresswire.com/article/935636763>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.